Look at these pore souls. Dr. Scott Walter — a board-certified dermatologist in the Denver area — is raising awareness about ...

Eyelash extensions have become a popular beauty treatment, but could they be putting your eye health at risk? Health ...

An eye doctor has opened up on finding parasitic eye infections in his patients that he says are commonly caused by one ...

This common bedroom habit could increase the risk of your lashes becoming infested with demodex: microscopic mites that mate ...

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert ...

The company’s lead candidate TP-03, is a novel drug that targets the Demodex mite nervous system to kill the mites. Read More on TARS: Tarsus Pharmaceuticals NewsMORE Related Stocks Indices ...

Generated $48.1 million in XDEMVY® net product sales driven by more than 41,400 bottles delivered to patients in the third quarterStrengthened ...

As the first treatment cleared by the FDA for Demodex blepharitis, an eye disease estimated to affect 25 million people in the U.S. alone, Tarsus Pharmaceuticals’ Xdemvy is pitting its might ...

These launches included products with strong clinical value for conditions without existing treatments, such as RSV vaccines, ...

"Treatment with topical ivermectin may improve the symptoms of rosacea through modulation of the skin microbiome beyond decreasing Demodex," the authors concluded. "The results of this study,” they ...

Attendees will participate in a dynamic, interactive learning experience where leading eyecare professionals tackle pressing ...

The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex ...